Bristol Myers Squibb (BMY) Non-Current Deferred Tax Liability (2010 - 2026)

Bristol Myers Squibb (BMY) has reported Non-Current Deferred Tax Liability for 14 consecutive years, with $222.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 10.12% year-over-year to $222.0 million in Q2 2026; TTM through Jun 2026 was $222.0 million, a 10.12% decrease from a year earlier, with the FY2025 full-year figure at $222.0 million, down 95.14% from the prior year.
• Non-Current Deferred Tax Liability was $222.0 million for Q2 2026 at Bristol Myers Squibb, up from $211.0 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $5.0 billion in Q4 2022 and troughed at $211.0 million in Q1 2026.
• A 5-year average of $1.6 billion and a median of $451.5 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability advanced 7.77% in 2024 and slumped 95.14% in 2025, its largest moves.
• Over 5 years, Non-Current Deferred Tax Liability stood at $5.0 billion in 2022, then slipped by 1.27% to $4.9 billion in 2023, then retreated by 6.77% to $4.6 billion in 2024, then tumbled by 95.14% to $222.0 million in 2025, then changed by 0.0% to $222.0 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $222.0 million (Q2 2026), $211.0 million (Q1 2026), and $222.0 million (Q4 2025), per Business Quant data.